December 09, 2021
1 min read
Save

Aerie, Santen reach licensing agreement for glaucoma drugs

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Aerie and Santen have entered an agreement for Rhopressa and Rocklatan in Europe, China, India, Commonwealth of Independent State countries, parts of Latin America and Oceanic countries, according to a company press release.

“We are delighted to announce this development and commercialization agreement with Santen, a leading global ophthalmology company, which will extend the benefits of our unique products to patients with glaucoma or ocular hypertension in Europe and several other global regions,” Benjamin F. McGraw II, PharmD, interim executive chairperson of the board of directors for Aerie, said in the release.

Rhopressa (netarsudil ophthalmic solution 0.02%) and Rocklatan (netarsudil and latanoprost ophthalmic solution 0.02%/0.005%) are both approved in the US. The drugs are also approved in Europe, where the drugs are known as Rhokiinsa and Roclanda, respectively.

According to the agreement, Aerie will receive an upfront payment of $88 million, followed by up to $77 million in sales, development and regulatory milestones, according to the release. Additionally, Aerie is eligible to receive up to 25% of net sales of the products.

Santen is responsible for sales, marketing and pricing decisions in the territories outlined in the agreement, according to the release.